TP53 and myelodysplastic syndrome: The pathologic activation of TP53 in ribosomopathies such as DBA and MDS is significant because both TP53 overexpression and mutations in TP53 are associated with impaired erythropoiesis, resistance to conventional therapies, and worsened overall survival rates in these patients [1,4].